Parent company Predictive Technology Group made the announcement ahead of the 74th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo in Denver, where the test was introduced.
ARTguide is a first-in-kind, noninvasive diagnostic tool for assessing the risk of endometriosis and other inherited causes of infertility. Specifically, ARTguide is indicated for women who are having fertility issues and considering the use of assisted reproductive technologies (ART) such as in vitro fertilization.
ARTguide uses next-generation sequencing to assess patients for mutations in 11 different genes known to influence the risk of fertility.
Furthermore, patients will be evaluated for more than 750 genetic markers known to be related to endometriosis, using a proprietary algorithm. The algorithm was designed using tens of thousands of patient samples and billions of genetic sequences.
“I am confident that the ARTguide™ test will help couples challenged with infertility to have healthy babies transforming the lucrative assisted reproductive technology market,” Bradley Robinson, CEO of Predictive Technology Group, said in a press release. “ARTguide™ will provide ‘must-have’ information for couples and their physicians selecting an optimal course of care.”
Predictive Diagnostics, recently formed after a series of strategic acquisitions, will process ARTguide in its new clinical laboratory improvement amendments (CLIA)-certified laboratory in Salt Lake City.
Over the next few months, the company plans to launch ARTguide at six test locations. ARTguide will then be made available to patients with infertility across the U.S. in the second quarter of 2019.
Endometriosis leads to the development of endometrial lesions, which can cause significant bleeding and inflammation and can have a major effect on a woman’s quality of life. It can also lead to infertility.
Predictive Technology Group uses data analytics for the development of diagnostic tools to improve patient care.
Its subsidiary, Predictive Therapeutics, uses genetic and other data to design new tools that can assess a person’s risk of illness. The company also develops therapeutic products intended to recognize, prevent, and treat diseases.